• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Pittsburgh’s Cohera Medical pulls in $10 million in Series C tranche

Pittsburgh’s Cohera Medical pulls in $10 million in Series C tranche

January 25, 2010 By MedCity News

By Brandon Glenn

MedCity News logo

PITTSBURGH, Pennsylvania — Cohera Medical Inc., which is developing a tissue adhesive for use in tummy-tuck surgeries, received a $10 million investment commitment, the first of what it hopes will lead to a $25 million Series C round.

The $10 million commitment comes from its two major prior investors. The company plans to begin fundraising in March, with insiders getting the first shot, CEO Patrick Daly said.

The company raised a $6.8 million Series A round from private investors in 2006, followed by a $16.1 million Series B round in 2008. The Series B round was led by Pittsburgh’s Bradford Capital Partners and included participation from previous investors led by San Francisco-based Kern Whelan Capital LLC.

Asked if he was confident in Cohera’s prospects for raising the full $25 million, Daly said, “We believe what we’ve done as a company is going to make that round something that people will be interested in.”

The company’s lead product, TissuGlu, is designed to minimize fluid accumulation and other problems associated with abdominoplasty, or “tummy-tuck” surgery. In December, Cohera said it had treated with TissuGlu the first of about 40 patients in a clinical study in Germany. The company is continuing to enroll patients in the study, Daly said.

Cohera plans to seek CE Mark approval in the European Union this summer. The company hopes to begin enrolling patients in U.S. clinical trials in the fourth quarter, Daly said.

Patients who undergo tummy tucks require the insertion of drains to remove fluids that accumulate under the skin, but sometimes excess fluid still accumulates, necessitating another surgery. TissuGlu aims to strongly adhere to the skin that’s cut during surgery, reducing the amount of collected fluid and the time that drains need to be inserted, according to Cohera. Unlike some other strong “super-glue” adhesives used in tummy tucks, TissuGlu is safe for internal use, Cohera says.

Daly estimated TissuGlu’s market opportunity at between $500 million and $750 million from 2011 to 2015, according to press release.

The company is also developing an adhesive for securing soft tissues to implantable devices, such as hernia mesh, and a small-bone adhesive.The mesh product is currently in animal trials and the company expects it to be its second product to hit the market. Daly declined to provide a time frame for the mesh or bone products entering human trials.

Cohera is a portfolio company of economic development group Pittsburgh Life Sciences Greenhouse, which invested $250,000 in the company.

Filed Under: Business/Financial News, News Well Tagged With: Cohera Medical Inc.

More recent news

  • Medtronic reports first patient treated in study of multi-organ denervation for hypertension
  • Baxter turns to an automation company for its new CEO
  • Pristine Surgical appoints new CFO
  • Boston Scientific wins expanded FDA nod for Farapulse PFA
  • FDA warns on issue with J&J Abiomed pump controllers related to 3 deaths

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy